Ventilator-associated pneumonia in the era of COVID-19 pandemic: How common and what is the impact?

Paul-Henri Wicky1, Michael S. Niedermann2,3 and Jean-François Timsit1,4*

Abstract
We reviewed similarities and differences of ventilator associated pneumonia in Sars-Cov2 infection and with other ARDS. The differences in epidemiology and outcome will be detailed. Possible explanations of differences in pathophysiology of VAP in Sarscov2 infections will be cited and discussed.

Keywords: COVID-19, ARDS, Ventilation-associated pneumonia, Superinfections, Prognostic

Addressing the common issue of antimicrobial stewardship for bacterial superinfections in severe SARS-CoV-2 infections is particularly challenging, especially with the uncertainties about how to diagnose ventilator-associated pneumonia (VAP) and tracheobronchitis (VAT). As compared to other viral pneumonias, the reported incidence of community-acquired pulmonary bacterial coinfections with COVID-19 is as low as 3% and 5–16% for ward and Intensive Care Units (ICU) patients respectively [1, 2]. However, the frequency of VAP is uncertain, and its incidence, characteristics and prognosis remain to be further explored (Fig. 1).

Significant disparities exist in the epidemiology of VAP, arguing for a standardization of definitions. Blonz et al., reported a crude incidence rate of 48.9% [1] in agreement with incidence rates ranging from 48 to 79% [3–6] in other cohorts. This rate contrasts substantially with the 29% observed in a multicenter study performed during the first COVID-19 wave in Italy [7]. In a retrospective study of 91 patients with COVID-19 respiratory failure (81 on a ventilator for > 48 h), Maes et al. reported a hazard ratio of 2.1, compared to non-COVID-19 patients, and an incidence of 79% with VAP [6]. In another study of 568 COVID-19 patients, 50.5% had either VAP or VAT, a higher incidence than was seen in influenza pneumonia or non-viral pneumonia [7]. It is clearly difficult to differentiate VAT from VAP in severe SARS-CoV-2 infections where modifications of chest radiographic infiltrates might be related to technical problems or intercurrent non-infectious events [8].

Additionally, VAP incidence may vary according to the bacteriological test used. Indeed, to avoid healthcare workers (HCW) contamination when the diagnosis of VAP is suspected, the use of bacteriological samples and bronchoscopy have been reduced, and gram stain examination not performed. The majority of VAPs were diagnosed based on bacteriological analysis from endotracheal aspirates (42.6%) in the study by Blonz et al., similar to the methods chosen by others [6]. Bronchoalveolar lavage (BAL) accounted for a quarter of sampling technique in COVID-ARDS patients, compared to 60% in non-COVID ARDS, in one study [3]. Importantly, quantitative distal as well as proximal samples were performed, but some authors only considered distal samples [3, 4], and others also included molecular methods [5, 9].

The increased risk of VAP in SARS-CoV-2 infections, as compared to other ARDS, may have been due to multiple factors including: less rigorous use of standard
prevention strategies during COVID-19, disease and therapy-associated immune impairment, more prolonged duration of mechanical ventilation, prolonged use of sedation, and higher risk for pulmonary infarction with associated superinfection. Although ICU overcrowding could also have been a factor, the study of Blonz et al. was done in an “uninundated” region where ICUs had adequate facilities for providing usual level of patient care, and thus there were less potential breaches in contact isolation. Similarly, in another single center study, a VAP rate reaching 74% was observed during both the first overcrowded wave and during the second wave where the ICU beds were sufficient [10].

SARS-CoV-2 ARDS patients have different clinical features than other ARDS patients, characterized by more profound hypoxia, and in comparative studies, the duration of mechanical ventilation was twice as long in COVID-19 patients compared with other types of ARDS [4, 5]. The extensive use of prone positioning could also have affected VAP incidence, and this therapy has been used in 67–83% of COVID-19 patients, generally twice as often as in influenza ARDS [3, 6]. Another difference with COVID-19 is the high risk of initial pulmonary emboli, which could predisposes to pulmonary infarction and secondary superinfections [11]. Immune alterations of the lung observed in ARDS patients [12] and COVID-19 patients, could be further amplified in SARS-CoV-2 infections by the use of corticosteroids or interleukin-receptor antagonists, as is suggested by some studies [13, 14], but not confirmed by recent randomized controlled trials [15].

VAP complicating SARS-CoV-2 infections occurred often late during mechanical ventilation [1, 4, 5]. Pathogens recovered are dependent on the local epidemiology. Enterobacteriales accounted for two thirds of VAP (mainly Escherichia coli and Klebsiella pneumoniae), with half of these organisms being resistant to 3rd-generation cephalosporins. Notably, a significantly higher rate of Extended Spectrum Beta-lactamase-producing Enterobacteriales (ESBL-PE) have been reported, compared to historical non-COVID-19 controls (72% vs 47%), and Aspergillus appears more common in COVID-19 respiratory failure than in other populations [3]. Interestingly, bloodstream infections (BSI) occurred in 10.6% of cases while pneumonia represented 21% of the source of BSI. Although prior antibiotic therapy can generally predispose to resistant organisms, Blonz et al. found that initial empiric therapy seemed to reduce the risk of polymicrobial VAP [1].

Finally, some studies found an important rate of complicated VAP with lung abscesses and empyema [1]
Substantial perfusion defects and impaired antibiotic diffusion into the parenchyma, could reasonably explain these failures, due to insufficient antibiotic concentration in the lung. We think that close therapeutic drug monitoring should be used in these patients with augmented renal clearance, to prevent therapeutic failures [12]. Given the high risk of pulmonary superinfections, and antibiotic failure, considerable effort to promote and implement prevention policies are of key importance especially in case of pandemic and healthcare system overcrowding. In this particular situation, even if MDR bacteria colonization is frequent, selective digestive or oral decontamination, or early intravenous antibiotic prophylaxis might be tested.

Abbreviations
ICU: intensive care units; VAP: ventilator-associated pneumonia; ARDS: acute respiratory distress syndrome; VAT: ventilator-associated tracheobronchitis; HCW: health care workers; BAL: bronchoalveolar lavage; ESBL-PE: extended spectrum beta-lactamase producing enterobacterales; BSI: blood stream infection;

Authors' contributions
PHW, MN and JFT: Conception and writing. All authors read and approved the final manuscript.

Funding
JFT was supported by the Innovative Medicines Initiative Joint Undertaking (Grant No. 115523) [Combatting Bacterial Resistance in Europe], resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2020) and European Federation of Pharmaceutical Industries and Associations companies’ in-kind contributions.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
JFT declares advisory board participation for Pfizer, Merck, Bayer pharma, Shionogi, Medimmune, Paratek, Gilead, Beckton-Dickinson, lecture fees from Merck, Biomerieux, Pfizer and Grants to his research group from Pfizer, Merck, ThermoFisher all outside the submitted work. The other authors declare no competing interests.

Author details
1 Medical and Infectious Diseases ICU (Mi2), AP-HS, Bichat Hospital, 75018 Paris, France. 2 Department of Medicine, Weill Cornell Medicine, New York, USA. 3 Pulmonary and Critical Care Medicine, New York Presbyterian/Weill Cornell Medical Center, New York, USA. 4 IAME, INSERM, University of Paris, 75018 Paris, France.

Received: 3 April 2021 Accepted: 8 April 2021
Published online: 21 April 2021

References
1. Blonz G, Koutetchat A, Chudeau N, Pontes E, Lober J, Lemeur A, et al. Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region. Crit Care. 2021;25:6–12.
2. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, Puerta-Alcalde P, Garcia-Pou- ton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83–8.
3. Razazi K, Arrestier R, Haudebourg AF, Benelli B, Carteaux G, Decousser J-W, et al. Risks of ventilator-associated pneumonia and invasive aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease. Crit Care. 2020;24(1):699.
4. Luyt C-E, Sahnoun T, Gautier M, Vidal P, Burel S, de Chambrun MP, et al. Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study. Ann Intensive Care. 2020;10(1):158.
5. Maes M, Higgenson E, Pereira-Dias J, Curran MD, Parmar S, Khokhar F, et al. Ventilator-associated pneumonia in critically ill patients with COVID-19. Crit Care. 2021;25(1):25.
6. Rouzé A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021;12:188–98.
7. Giacobbe DR, Baragli D, Enrile EM, Dentone C, Vena A, Robba C, et al. Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with COVID-19: a multicenter study. J Clin Med. 2021;10(4):555.
8. Nair GB, Niederman MS. Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med. 2015;41(1):34–48.
9. Maataoui N, Chemali L, Patner J, Tran Dinh A, Le Fèvre L, Lorrat-Jacob B, et al. Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit. Eur J Clin Microbiol Infect Dis. 2021;71:1–8.
10. Coultou D, Cally R, Sarfati F, Desaint P, Fraissé M, Plantefève G. Causes and timing of death in critically ill COVID-19 patients. Crit Care. 2021;25(1):79.
11. Helms J, Taucquad C, Severeac F, Leonard-Lorant T, Chana M, Delbranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;6:1089–98.
12. Luyt C-E, Bouadma L, Morris AC, Dhanani JA, Kollef M, Lipman J, et al. Pulmonary infections complicating ARDS. Intensive Care Med. 2020;46:2:2168–83.
13. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for the management of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa954.
14. Buetti N, Rucky S, de Montmollin E, Reignier J, Terzi N, Cohen Y, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med. 2021;47(2):180–7.
15. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv [Internet]. [cited 2021 Mar 16]. Available from: https://doi.org/10.1101/2021.02.11.21249258v1

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.